Japan Tissue Engineering Co., Ltd. (7774.T) Stock
Japan Tissue Engineering Co., Ltd.

Company profile
Japan Tissue Engineering reported revenue of 2.46 billion JPY for fiscal year 2025, down 2.3% from fiscal year 2024. Our analysis of its filings shows revenue growing from 2.03 billion JPY in fiscal year 2023 to 2.46 billion JPY in fiscal year 2025, 9.9% a year on average. Japan Tissue Engineering reports about 200 full-time employees.
What stands out
- It reported a net loss of 255.30 million JPY in fiscal year 2025, after a profit of 143.17 million JPY in fiscal year 2024.
- Its net profit margin over the last four reported quarters was -13.4%, against a median of 2.0% for 6 listed companies of similar size in its industry.
- It spent 506.73 million JPY on research and development in fiscal year 2025, 20.6% of its revenue.
Figures from company filings; latest fiscal year ended March 31, 2025.
About Japan Tissue Engineering Co., Ltd.
Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Contract, and Lab Site Project segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it offers EPI-MODEL, a reconstructed human epidermis model. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. operates as a subsidiary of Teijin Limited.
Largest shareholders
- Teijin Limited57.72%
- Nidek Co., Ltd.10.41%
- Yoko Maeda0.8431 %0.84%
- Daisuke Gomi0.8126 %0.81%
- Yosuke Ozawa0.719 %0.72%
Share of the company, as of September 25, 2026
Leadership
- Kazuto Yamada — Executive Officer, President, CEO & Director, 52
- Toshihiro Osuka — Senior Managing Executive Officer & Director, 68
How much revenue does Japan Tissue Engineering make?
Japan Tissue Engineering reported 2.46 billion JPY in revenue for fiscal year 2025, down 2.3% from 2.51 billion JPY in fiscal year 2024.
What companies are similar to Japan Tissue Engineering?
Listed companies of a similar size in the same industry (various healthcare equipment manufacturing) include Nipro Corporation (8086.T), Mani, Inc. (7730.T), Medikit Co.,Ltd. (7749.T), JMS Co.,Ltd. (7702.T).
Has Japan Tissue Engineering made a profit in recent years?
Net income by fiscal year: FY2021, a loss of 466.62 million JPY; FY2022, a loss of 497.89 million JPY; FY2023, a loss of 729.32 million JPY; FY2024, 143.17 million JPY; FY2025, a loss of 255.30 million JPY. It reported a net loss in 4 of these 5 years.
How does Japan Tissue Engineering's profit margin compare with similar companies?
Net profit margin over the last four reported quarters: Japan Tissue Engineering, -13.4%; Nipro Corporation (8086.T), 1.6%; Mani, Inc. (7730.T), 21.9%; Medikit Co.,Ltd. (7749.T), 12.7%; JMS Co.,Ltd. (7702.T), -1.3%; Create Medic Co., Ltd. (5187.T), 2.5%; Cyfuse Biomedical K.k. (4892.T), -260.7%.
Company Information
Data as of .
How to cite: DataPorium, “Japan Tissue Engineering Co., Ltd. (7774.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/7774.T